Xcellbio is a venture-backed company driven by its mission to enhance the performance and safety of cell and gene-based therapies through the design and development of revolutionary technology platforms. The company's commercial instruments and AI-driven software allow researchers to discover novel insights into immune and tumor biology and enable the translation of these insights at patient scale through the development of its pioneering cell therapy manufacturing platform.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/19/22 | $27,500,000 | Series B |
Casdin Capital Dynamk Capital Formic Ventures HBM Genomics LabCorp Viking Global Investors | undisclosed |
